At the forefront of cancer innovation, researchers from Memorial Sloan Kettering Cancer Center (MSK) showcased groundbreaking advancements at the 2026 American Association for Cancer Research (AACR) Annual Meeting, held in San Diego. This premier scientific gathering spotlighted transformative strides in understanding cancer biology, targeting tumor ecosystems, unraveling resistance mechanisms, and harnessing computational power to decode tumor complexities, establishing new paradigms in oncology research and therapy.
One of the most compelling breakthroughs involves the engineering of CAR T cells to target uPAR, a surface protein intricately involved in tissue remodeling and wound healing. This protein’s persistent overexpression in tumor cells and supportive cells within the tumor microenvironment renders it an ideal immunotherapeutic target. Preclinical studies demonstrated that uPAR-directed CAR T cells effectively shrink solid tumors across lung, pancreatic, and ovarian cancer models in mice, even eliminating metastases in certain cases. This dual-action targeting disrupts not only the malignant cells but also the fibrotic and immunosuppressive stroma, a barrier that has notoriously hindered immunotherapy efficacy in solid tumors. Remarkably, these engineered cells spare normal immune counterparts, suggesting a promising therapeutic window and underscoring the potential expansion of CAR T therapies beyond hematologic malignancies.
MSK’s work transcends traditional tumor-centric views by framing cancer as a complex, interconnected ecosystem of malignant cells and their microenvironmental niches. The Marie-Josée and Henry R. Kravis Cancer Ecosystems Project, under the scientific guidance of Scott Lowe, PhD, epitomizes this approach. By unraveling the interactive cellular and molecular networks sustaining tumor growth, this initiative seeks to pioneer therapies that dismantle not only cancer cells but also their protective microenvironments. Such integrated strategies could revolutionize the management of historically intractable cancers.
Harnessing cutting-edge computational biology, Dana Pe’er, PhD, and colleagues unveiled how select cancer cell subtypes orchestrate their surroundings to establish a self-perpetuating tumor ecosystem. Utilizing spatial transcriptomics coupled with an innovative algorithm termed Wasserstein Wormhole, they delineated how ‘basal’ cancer cells attract myeloid immune populations that fortify the tumor’s defenses. Ablation of these basal cells in murine pancreatic cancer models resulted in ecosystem collapse, rendering tumors vulnerable to immune attack. These insights reveal that targeting cellular heterogeneity and intercellular communication within tumors can disarm the cocooning microenvironment that fosters therapeutic resistance.
Further computational dissection revealed highly plastic progenitor-like cancer cells in early pancreatic tumors that, when unchecked by tumor suppressor p53, fuel malignant progression through reprogramming their niche. This discovery clarifies the pivotal tumor-suppressive role of p53 in curbing cellular plasticity, offering new angles for therapeutic intervention aimed at reestablishing tissue homeostasis and thwarting early oncogenesis.
Immunomodulatory dynamics within tumors also received critical scrutiny, as Omar Abdel-Wahab, MD, presented pioneering research on the role of RNA splicing in mediating T cell exhaustion—a phenomenon that limits the efficacy of immunotherapies like checkpoint inhibitors. His team uncovered unique RNA splice variants in CD8+ T cells infiltrating melanoma, distinct from those in functional T cells. By manipulating RNA splicing pathways, they enhanced the anti-tumor capability of exhausted T cells, offering a molecular blueprint for reinvigorating immune responses and overcoming immune evasion in tumors.
The challenge of therapeutic resistance was starkly illuminated in the context of HER2-targeted antibody-drug conjugates (ADCs), particularly trastuzumab deruxtecan (T-DXd). Sarat Chandarlapaty, MD, PhD, alongside Joshua Drago, MD, MS, probed tumor biopsies from patients who relapsed following T-DXd treatment. Their analyses revealed two dominant resistance mechanisms: downregulation or loss of HER2 expression and mutational alterations that hinder ADC binding. Importantly, co-targeting HER2 and the alternative antigen TROP2 with combined ADC regimens achieved superior efficacy in preclinical models, suggesting a translational path towards overcoming resistance and refining targeted therapy paradigms.
In a novel exploration of tissue-level protection against cancer, Mara Sherman, PhD, focused on the pancreas’ mesenchymal stroma and its secretion of KITL, a signaling molecule crucial for maintaining tissue architecture and limiting cellular plasticity. Loss of KITL was observed during early stages of pancreatic tumorigenesis, facilitating cell state changes that promote malignancy. Sherman’s findings underscore the importance of stromal-tumor interactions and hint at preventive strategies that bolster tissue integrity to counteract cancer initiation.
Broader genomic investigations highlighted the influence of hereditary genetics beyond mere cancer susceptibility to encompass tumor evolution and mutational landscapes. Jian Carrot-Zhang, PhD, presented a compelling study demonstrating that inherited germline variants shape which somatic mutations tumors acquire. This multi-ancestral analysis unveiled population-specific genetic influences, emphasizing the necessity for personalized medicine approaches that account for genetic diversity and its impact on tumor biology and treatment responsiveness.
Another striking advance pertained to the body’s response to viral infections associated with cancer risk. Computational biologist Caleb Lareau, PhD, revealed how persistent Epstein-Barr virus (EBV) infection—implicated in autoimmune diseases and cancers—is modulated by host genetic variants identified through large-scale genomic and viral DNA data mining. By integrating data from hundreds of thousands of individuals, this research identified specific genetic loci linked to EBV persistence and related chronic diseases, opening avenues for targeted interventions aiming to mitigate virus-associated cancer risk.
Harmonizing these multifaceted discoveries, MSK’s research demonstrates unparalleled integration of molecular biology, computational science, immunology, and clinical insights. The collective efforts presented at AACR 2026 not only deepen our mechanistic understanding of cancer as a dynamic ecosystem but also propel the field toward innovative therapeutic strategies designed to disrupt tumor support networks, overcome resistance, and personalize treatment based on genetic and molecular cancer ecosystems.
In sum, the 2026 AACR Annual Meeting illuminated the future trajectory of oncology: a landscape where cutting-edge bioengineering, high-resolution spatial profiling, RNA biology, and germline-genome interactions converge to transform cancer diagnosis, prevention, and therapy. With these insights, MSK and collaborators are charting a bold course toward more effective and durable cancer treatments, fostering hope for patients facing some of the most formidable malignancies.
Subject of Research: Cancer Biology and Therapeutics, Tumor Microenvironment, Immuno-Oncology, Computational Oncology, Genetic Determinants of Cancer Progression, Resistance Mechanisms, Viral Oncology
Article Title: Emerging Paradigms in Cancer Ecosystems and Therapeutics: Insights from Memorial Sloan Kettering at AACR 2026
News Publication Date: 2026
Web References:
- https://www.aacr.org/meeting/aacr-annual-meeting-2026
- https://www.mskcc.org/news/treating-her2-amplified-early-stage-rectal-cancer-to-improve-quality-of-life
- https://www.mskcc.org/news/new-kras-targeted-therapy-shows-promise-against-pancreatic
- https://www.mskcc.org/news/can-mrna-vaccines-fight-pancreatic-cancer-msk-clinical-researchers-are-trying-find-out
References:
- Cell (2026) on engineered uPAR-targeting CAR T cells and spatial transcriptomics studies
- Cancer Discovery (2026) on resistance mechanisms to HER2-targeted ADCs
- Nature (2025) on genetic determinants of Epstein-Barr virus persistence
Image Credits: Memorial Sloan Kettering Cancer Center
Keywords: Cancer Ecosystems, CAR T Cell Therapy, Tumor Microenvironment, RNA Splicing, Immunotherapy Resistance, HER2 Antibody-Drug Conjugates, Pancreatic Cancer, Genetic Variation, Epstein-Barr Virus, Computational Biology, Spatial Transcriptomics
